Tag archive for ‘RYLP’
Relypsa: Analyzing April Results of the Veltassa Launch (RLYP, Buy, $14.00)
Investment Overview Investors are closely watching the launch progress of Veltassa following its December 2015 introduction. Medicare and managed care have set up barriers to prescribing that makes getting a prescription filled for a new drug laborious and time consuming and sometimes futile. With very few exceptions, most new product launches have disappointed investors to the […]
ZS Pharma: Astra Zeneca to Acquire ZS Pharma at $90 per Share-DARN (ZSPH, $90)
On Friday, November 9, 2015 Astra Zeneca entered into a definitive agreement to buy ZS Pharma in an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share. This values the Company at $2.7 billion or $2.5 billion if you subtract out $200 million of cash […]